Randomized clinical trial shows lung cancer incidence varies with canakinumab dose in patients without clonal hematopoiesis mutations, suggesting targeted treatment implications.
Supplementary Figure S2 shows cumulative incidence of lung cancer by treatment in patients without CH mutations, stratified by the canakinumab dose.
No takes yet. Share an insight, caveat, or question.
Woo et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: